BelgFre schreef op 3 juli 2018 18:23:
[...]
July 3 (Reuters) - ABIVAX SA ABVX.PA :
* ABIVAX RELEASES POSITIVE TOP LINE DATA FROM ABX464-005
PHASE 2A
STUDY IN HIV INFECTION
* EXTENDED DOSING WITH ABX464 OBSERVED TO BE SAFE AND
WELL-TOLERATED
* DECREASE IN TOTAL HIV DNA IN BLOOD OBSERVED WITH LONGER
TREATMENT
* FOR FIRST TIME, HIV DNA DECREASE OBSERVED IN RECTAL TISSUE
* ABIVAX PLANNING FOR PHASE 2B
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom:)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))